KRAS and colorectal carcinoma: Overall, although these studies established a certain links between CIMP subgroups and the MSI, BARF and KRAS genetic phenotypes in CRC patients [125], again, when analyzing clinical outcome results across studies, caution should be taken because the loci marker panel and criteria for CIMP, and the levels of these genetic mutations vary from study to study.